Pimavanserin has positive results for dementia related psychosis

Shares of Acadia Pharmaceuticals Inc. ACAD, +63.36% rocketed 87% toward a 4-year high in premarket trading Monday, after the biopharmaceutical company said a phase 3 trial of its treatment for dementia-related psychosis met its primary endpoint. The company said pimavanserin achieved “robust statistical superiority” over placebo, with longer time to relapse of psychosis with pimavanserin compared with placebo. Acadia said the study will be stopped early based on the study’s findings. The company plans to meet with the Food and Drug Administration regarding a supplemental new drug application (NDA) submission in 2020.